This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy


See what Vera Hirsh thinks about the importance of sequencing!

The prevalence of T790M acquired resistance mutation in patients treated with GIOTRIF® is similar to first-generation TKIs3

Patients receiving a third-generation EGFR TKI following GIOTRIF® treatment had an improved OS benefit versus gefitinib1

 

  • Around 50% of patients who progress on GIOTRIF® have an acquired T790M mutation3
  • In LUX-Lung 7, the same percentage of patients in the GIOTRIF® and gefitinib arms received a subsequent third-generation EGFR TKI (13.7% and 15.2%, respectively)2
  • Hazard ratio for OS suggested an improvement in favour of GIOTRIF® versus gefitinib in patients who received a third-generation EGFR TKI with median OS not reached in the GIOTRIF® arm and 46.0 months in the gefitinib arm (HR=0.51; 95% CI, 0.17–1.52; P=0.22)2

No difference in the proportion of GIOTRIF®–treated patients receiving subsequent therapies after 1st-line therapy1
 

  • GIOTRIF® OS benefit in del19 patients is not attributable to follow-up treatment1
  • In LUX-Lung 7, 73% of GIOTRIF®–treated patients received subsequent therapy with chemotherapy and 46% with an EGFR TKI2
  • In LUX-Lung 3, 75% of chemotherapy-treated and 71% of GIOTRIF®–treated patients received subsequent therapy with an EGFR TKI or chemotherapy,respectively1

TKI=tyrosine kinase inhibitor; OS=overall survival; EGFR =epidermal growth factor receptor

Is this information compelling to you?

Request contact
from Boehringer Ingelheim

References

  1. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.
  2. Paz-Arez L et al. Ann Oncol. 2017; doi: 10.1093/annonc/mdw611.
  3. Wu SG et al. Oncotarget. 2016;7(11):12404-12413.
  4. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
  5. Wu YL et al. Lancet Oncol. 2014;15(2):213-222.
  6. Park K et al. Lancet Oncol. 2016;17(5):577-589.
  7. Soria JC et al. Lancet Oncol. 2015;16(8):897-907.
  8. Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.
  9. GIOTRIF® (afatinib) Summary of Product Characteristics, 2016.
  1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

  2. Wu YL et al. Lancet Oncol. 2014;15(2):213-222.

  3. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.

  4. Park K et al. Lancet Oncol. 2016;17(5):577-589.

  5. Soria JC et al. Lancet Oncol. 2015;16(8):897-907.

  6. Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.

  7. Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.

  8. Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.

  9. Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

  10. Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.

  11. Paz-Arez L et al. Ann Oncol. 2017; doi: 10.1093/annonc/mdw611.

  12. GIOTRIF® (afatinib) Summary of Product Characteristics, 2016.

Report an adverse event

If you wish to report an adverse event (AE) after treatment with one of our products, please select your site from the link below. This will allow reporting of AEs in line with the reporting procedure effective in your country for reporting.

Boehringer Ingelheim local websites
Back to top